# Taha Merghoub

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/taha-merghoub/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,083 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 93 |
| i10-index | 201 |
| Last Known Institution | Cornell University |
| OpenAlex ID | https://openalex.org/A5002951130 |
| ORCID iD | https://orcid.org/0000-0002-1518-5111 |
| Works | 878 |

## Researcher papers

- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade](https://scholariq.org/papers/clonal-neoantigens-elicit-t-cell-immunoreactivity-and-sensitivity-to-immune/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing](https://scholariq.org/papers/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas](https://scholariq.org/papers/relief-of-profound-feedback-inhibition-of-mitogenic-signaling-by-raf-inhibitors/)
- [Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers](https://scholariq.org/papers/transcriptional-programs-of-neoantigen-specific-til-in-anti-pd-1-treated-lung/)
- [Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence](https://scholariq.org/papers/loss-of-nf1-in-cutaneous-melanoma-is-associated-with-ras-activation-and-mek/)
- [Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth](https://scholariq.org/papers/prevention-of-dietary-fat-fueled-ketogenesis-attenuates-braf-v600e-tumor-growth/)
- [Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer](https://scholariq.org/papers/neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-non-small-cell-lung-cancer/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)

## Researcher university

- [Cornell University](https://scholariq.org/institutions/cornell-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.